AI Hype Won't Cut It: VCs Want Net Revenue Retention, Proprietary Data, Clinical Impact

AI In Healthcare Pitches: The Metrics Investors Want-and The Red Flags They Won't Ignore

AI is showing up in nearly every healthcare startup pitch. The real question investors ask: does the product create measurable value, or is it buzz with no backbone?

At the MedCity INVEST Digital Health conference in Dallas, a panel led by Neil Patel of Redesign Health pressed founders on what to highlight and what to avoid. On stage: Maddie Hilal of Oak HC/FT, Rohit Nuwal of TELUS Global Ventures, and Vickram Pradhan of Sopris Capital.

What founders should highlight

1) Net Revenue Retention (NRR). Show that existing customers are sticking around and buying more. If NRR is strong, you're proving value without waiting years for full profit-and-loss proof points.

Translate this into investor-ready proof: cohort-level NRR, expansion revenue by use case, churn reasons, and time-to-expansion. Share 2-3 customer references who grew their contracts and why.

2) Data quality and provenance. Better data drives better models and outcomes. Investors want to know the data you train on, the settings where your solution runs, and what makes the dataset proprietary or defensible.

Be explicit: data sources, sample sizes, patient diversity, feature stability, drift monitoring, labeling quality, and rights to use data for training and commercialization.

3) Clinical impact that is hard to argue with. Investors want proof that you improve outcomes or safety, shorten time-to-diagnosis, reduce readmissions, or streamline clinician workload with clear metrics. That clarity builds a path to payment, even in healthcare's "black box" of reimbursement.

Back it up with validated endpoints, pre/post deltas, peer-reviewed or externally validated results, and prospective or multi-site studies where possible. For solutions touching regulated workflows, map to clinical risk and, if applicable, regulatory plans. For context on AI/ML in medical devices, see the FDA's guidance on SaMD AI/ML policies: FDA AI/ML SaMD.

AI red flags investors called out

• Buzzwords without evidence. Saying "AI" everywhere without data, metrics, or outcomes to back it up.
• Mislabeling the tech. Calling a basic statistical or machine learning approach "AI" to impress the room. Be accurate about what you built.
• "Squishy" revenue. Inflated contracted revenue from pilots, multi-year totals presented as current revenue, or future scenarios framed as booked dollars. Be precise about ARR, GAAP revenue, pilots, and contract terms.

Make your pitch airtight: what to prepare

• Customer value: NRR, logo retention, expansion drivers, and customer payback period.
• Model performance: metrics by use case and setting; external validation; fairness checks across subgroups; drift tracking and retraining cadence.
• Clinical evidence: outcomes, endpoints, sample sizes, controls, and statistical significance; who validated the results and where.
• Data rights: contracts, de-identification methods, HIPAA/PHI handling, and audit trails.
• Commercial clarity: ICP, pricing, time-to-live, time-to-value, implementation burden, and ROI proof a CFO would accept.
• Go-to-market truth: pilots vs production, conversion rates, sales cycle length, and funnel math.

What this means for healthcare and finance leaders

If you buy or invest in AI, ask for NRR, clinical outcomes, and data lineage before you greenlight anything. Insist on clarity between pilots and production revenue. Push vendors to disclose where the model performs, where it fails, and how they manage risk.

If the startup can explain value in one slide using NRR, outcomes, and clean revenue numbers, you likely have a real product-not just a shiny demo.

Panel voices to note

Maddie Hilal emphasized NRR as a leading signal that customers see value, even before full P&L proof emerges.

Rohit Nuwal pressed for high-quality, proprietary data and transparency about the training and deployment environments.

Vickram Pradhan underscored clinical impact as the foundation that ultimately drives payment and enduring value.

Level up your team's AI fluency

If your team needs practical AI literacy to evaluate vendors and metrics with confidence, explore role-based learning paths here: Complete AI Training - Courses by Job.